A Phase 2 interventional study of Trastuzumab and Tucatinib in Metastatic Colorectal Adenocarcinoma, sponsored by Seagen Inc.. Completed at 56 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Colorectal Neoplasms by Pfizer — 6 open to participants now, 14 under way, 3 of them phase 3. Colorectal Neoplasms · Pfizer.
Among the 73 studies in Colorectal Neoplasms by Pfizer, this one is the 25th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2017, is one of 21 in phase 2, and was the 35th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →6 of the 73 studies in Colorectal Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, France, Spain
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 14 more countries
Ages 18+
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, Canada, China and 7 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, China and 5 more countries
Ages 18+
Pfizer
Ages 18+
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 27 · Phase 3 9 · Phase 4 2
First in 1999; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 72 across the 68 interventional studies, 1 across the 3 observational. Of the 58 that completed or were terminated, 28 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
2 of the studies in Colorectal Neoplasms by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05382364PfizerSafety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) | 2026-12-31 |
| NCT07909122PfizerReal-World Treatment Patterns and Effectiveness of Anti-EGFR- and Anti-VEGF-based Therapies in Left-sided RAS Wild-Type Metastatic Colorectal Cancer | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 73 studies in Colorectal Neoplasms by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body.
In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have confirmed -positive mCRC, as defined by having tumor tissue tested at a Clinical Laboratory Improvement Act (CLIA)-certified or International Organization for Standardization (ISO)-accredited laboratory, meeting at least one of the following criteria:
Exclusion Criteria
Toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1, with the following exceptions:
Known to have active infection
History of another within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.
Subjects with known active
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
Drug: Trastuzumab · Drug: Tucatinib
Randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
Drug: Trastuzumab · Drug: Tucatinib
Randomized cohort. Participants take tucatinib twice per orally every day. Participants who do not respond to therapy may have the option to receive tucatinib and trastuzumab.
Drug: Tucatinib
Given intravenously (into the vein; IV)
Also known as: Herceptin
Given orally
Also known as: ARRY-380, ONT-380, TUKYSA
Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B
cORR was defined as the percentage of participants with confirmed CR or PR according to RECIST v1.1. CR was defined as the disappearance of all target lesions and each target lymph node must have reduction in short axis to less than (\<)1.0 centimeter (cm). PR was defined as at least a 30 percentage (%) decrease in post-baseline sum of the diameters (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the baseline sum of diameters.
Time frame: Up to 46.6 months
ORR by 12 Weeks of Treatment Per RECIST v1.1 According to BICR Assessment
ORR per BICR by 12 Weeks was defined as the percentage of participants with CR or PR by 12 weeks of treatment, and before time of crossover (Cohort C), whichever came earlier. CR was defined as the disappearance of all target lesions and each target lymph node must have reduction in short axis to more than \<1.0 cm. PR was defined as at least a 30% decrease in post-baseline sum of the diameters (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the baseline sum of diameter.
Time frame: Up to 3 months
Duration of Response (DOR) Per RECIST v1.1 According to BICR Assessment
DOR was defined as the time from the first objective response (CR or PR that is subsequently confirmed) to documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as the disappearance of all target lesions and each target lymph node must have reduction in short axis to more than \<1.0 cm. PR was defined as at least a 30% decrease in post-baseline sum of the diameters (PBSD) (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the BSD. PD was defined as: at least one new malignant lesion, which also includes any lymph node that was normal at baseline (\<1.0 cm short axis) and increased to more than or equal to (\>=)1.0 cm short axis during follow-up or at least a 20% increase in PBSD taking as reference the minimum sum of the diameters (MSD). In addition, the PBSD must also demonstrate an absolute increase of at least 0.5 cm from the MSD.
Time frame: Up to 64.1 months
Progression-Free Survival (PFS) Per RECIST v1.1 According to BICR Assessment for Pooled Cohorts A+B
PFS was defined as the time from start of study treatment (Cohort A) or date of randomization (Cohort B) to documented disease progression (as determined by BICR per RECIST v1.1) or death from any cause, whichever occurred first. PD was defined as: at least one new malignant lesion, which also included any lymph node that was normal at baseline (\<1.0 cm short axis) and increased to \>=1.0 cm short axis during follow-up or at least a 20% increase in post-baseline sum of the diameters (PBSD) taking as reference the minimum sum of the diameters (MSD). In addition, the PBSD must also demonstrate an absolute increase of at least 0.5 cm from the MSD.
Time frame: Up to 64.1 months
Overall Survival (OS) in Pooled Cohorts A+B
OS was defined as the time from start of study treatment (Cohort A) or randomization (Cohort B) to date of death due to any cause.
Time frame: Up to 71.8 months
Number of Participants With Adverse Events (AEs): Interim Analysis
AE: Any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs): Events that were new or worsened on or after receiving the first dose of study treatment (tucatinib or trastuzumab) and up through 30 days after the last dose of study treatment (tucatinib or trastuzumab). Serious AE (SAE): An event that at any dose led to death; life-threatening; required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Relatedness was judged by investigator According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G) 3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE.
Time frame: Up to 49.3 months
Number of Participants With AEs: Final Analysis
AE: Any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs): Events that were new or worsened on or after receiving the first dose of study treatment (tucatinib or trastuzumab) and up through 30 days after the last dose of study treatment (tucatinib or trastuzumab). SAE: An event that at any dose led to death; life-threatening; required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Relatedness was judged by investigator According to NCI CTCAE version 4.03: Grade(G) 3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE.
Time frame: Up to 65.1 months
Number of Participants With AEs Resulting in Dose Modification: Interim Analysis
Dose modification included dose reduction and dose withheld by investigator due to AEs. Dose holds were defined as any instances where planned administration of the study drug was temporarily withheld or interrupted at the direction of the treating physician. Dose reductions of trastuzumab were not allowed; if trastuzumab could not be restarted after being held for a TEAE, it was discontinued.
Time frame: Up to 49.3 months
Number of Participants With AEs Resulting in Dose Modification: Final Analysis
Dose modification included dose reduction and dose withheld by investigator due to AEs. Dose holds were defined as any instances where planned administration of the study drug was temporarily withheld or interrupted at the direction of the treating physician. Dose reductions of trastuzumab were not allowed; if trastuzumab could not be restarted after being held for a TEAE, it was discontinued. Drug interruption included infusion interrupted (full dose received within 24hrs).
Time frame: Up to 65.1 months
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology): Interim Analysis
The following hematology laboratory parameters were assessed: Hemoglobin decreased; leukocytes decreased; neutrophils decreased and Platelets decreased. Treatment emergent laboratory abnormalities were defined as abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v4.03 was used for the lab parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.
Time frame: Up to 49.3 months
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology): Final Analysis
The following hematology laboratory parameters were assessed: Hemoglobin decreased; hemoglobin increased; leukocytes decreased; lymphocytes decreased; neutrophils decreased and Platelets decreased. Treatment emergent laboratory abnormalities were defined as abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v4.03 was used for the lab parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.
Time frame: Up to 65.1 months
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Chemistry): Interim Analysis
The following chemistry laboratory parameters were assessed: Potassium increased; potassium decreased; aspartate aminotransferase increased; creatinine increased; alkaline phosphatase increased; total bilirubin increased. Treatment emergent laboratory abnormalities were defined as abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v5.0 was used for creatinine increased. NCI CTCAE v4.03 was used for the other laboratory parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.
Time frame: Up to 49.3 months
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Chemistry): Final Analysis
The following chemistry laboratory parameters were assessed: Potassium increased; potassium decreased; aspartate aminotransferase increased; creatinine increased; alkaline phosphatase increased; total bilirubin increased; albumin decreased; calcium corrected for albumin decreased; calcium corrected for albumin increased; glomerular filtration rate (GFR), estimated decreased; glucose decreased; glucose increased; sodium decreased; sodium increased; calcium and ionized increased. Treatment emergent laboratory abnormalities: Abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v5.0 used for creatinine increased. NCI CTCAE v4.03 used for the other laboratory parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.
Time frame: Up to 65.1 months
Number of Participants With Clinically Significant Vital Signs: Final Analysis
Vital signs included temperature, oxygen saturation, systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate and weight. Vital signs were considered clinically significant: temperature: \>= 38 degree Celsius (C); oxygen saturation less than (\<)88%; SBP \>=120 millimeters of mercury (mmHg) or DBP \>=80 mmHg; SBP \>=140 mmHg or DBP \>=90 mmHg; SBP \>=160 mmHg or DBP \>=100 mmHg and heart rate \>100 beats per minute (bpm) and maximum decrease from baseline in weight in kilograms (kg).
Time frame: Up to 65.1 months
A total of 117 participants were enrolled at a total of 56 sites in the United States, Italy, France, Belgium, and Spain. The date of first participant enrollment was 23-Jun-2017. The date of last participant randomization was 02-Nov-2023.
| Milestone | Tucatinib+Trastuzumab (Cohort A) | Tucatinib+Trastuzumab (Cohort B) | Tucatinib Monotherapy (Cohort C) |
|---|---|---|---|
| Started | 45 | 41 | 31 |
| Completed | 0 | 0 | 0 |
| Not completed | 45 | 41 | 31 |
| Withdrew: Withdrawal by subject | 5 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Death | 28 | 26 | 17 |
| Withdrew: Participation terminated by sponsor | 11 | 13 | 13 |
cORR was defined as the percentage of participants with confirmed CR or PR according to RECIST v1.1. CR was defined as the disappearance of all target lesions and each target lymph node must have reduction in short axis to less than (\<)1.0 centimeter (cm). PR was defined as at least a 30 percentage (%) decrease in post-baseline sum of the diameters (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the baseline sum of diameters.
| Percentage of Participants | Tucatinib+Trastuzumab (Cohorts A+B) |
|---|---|
| Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B | 39.3 (28.8 to 50.5) |
ORR per BICR by 12 Weeks was defined as the percentage of participants with CR or PR by 12 weeks of treatment, and before time of crossover (Cohort C), whichever came earlier. CR was defined as the disappearance of all target lesions and each target lymph node must have reduction in short axis to more than \<1.0 cm. PR was defined as at least a 30% decrease in post-baseline sum of the diameters (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the baseline sum of diameter.
| Percentage of Participants | Tucatinib+Trastuzumab (Cohorts A+B) | Tucatinib Pre-Crossover (Cohort C) |
|---|---|---|
| ORR by 12 Weeks of Treatment Per RECIST v1.1 According to BICR Assessment | 28.6 (19.2 to 39.5) | 3.3 (0.1 to 17.2) |
DOR was defined as the time from the first objective response (CR or PR that is subsequently confirmed) to documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as the disappearance of all target lesions and each target lymph node must have reduction in short axis to more than \<1.0 cm. PR was defined as at least a 30% decrease in post-baseline sum of the diameters (PBSD) (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the BSD. PD was defined as: at least one new malignant lesion, which also includes any lymph node that was normal at baseline (\<1.0 cm short axis) and increased to more than or equal to (\>=)1.0 cm short axis during follow-up or at least a 20% increase in PBSD taking as reference the minimum sum of the diameters (MSD). In addition, the PBSD must also demonstrate an absolute increase of at least 0.5 cm from the MSD.
| Months | Tucatinib+Trastuzumab (Cohorts A+B) | Tucatinib Pre-Crossover (Cohort C) |
|---|---|---|
| Duration of Response (DOR) Per RECIST v1.1 According to BICR Assessment | 15.2 (8.9 to 20.5) | NA (NA to NA) |
PFS was defined as the time from start of study treatment (Cohort A) or date of randomization (Cohort B) to documented disease progression (as determined by BICR per RECIST v1.1) or death from any cause, whichever occurred first. PD was defined as: at least one new malignant lesion, which also included any lymph node that was normal at baseline (\<1.0 cm short axis) and increased to \>=1.0 cm short axis during follow-up or at least a 20% increase in post-baseline sum of the diameters (PBSD) taking as reference the minimum sum of the diameters (MSD). In addition, the PBSD must also demonstrate an absolute increase of at least 0.5 cm from the MSD.
| Months | Tucatinib+Trastuzumab (Cohorts A+B) |
|---|---|
| Progression-Free Survival (PFS) Per RECIST v1.1 According to BICR Assessment for Pooled Cohorts A+B | 8.1 (4.2 to 10.2) |
OS was defined as the time from start of study treatment (Cohort A) or randomization (Cohort B) to date of death due to any cause.
| Months | Tucatinib+Trastuzumab (Cohorts A+B) |
|---|---|
| Overall Survival (OS) in Pooled Cohorts A+B | 23.9 (18.7 to 28.3) |
AE: Any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs): Events that were new or worsened on or after receiving the first dose of study treatment (tucatinib or trastuzumab) and up through 30 days after the last dose of study treatment (tucatinib or trastuzumab). Serious AE (SAE): An event that at any dose led to death; life-threatening; required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Relatedness was judged by investigator According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G) 3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE.
| Participants | Tucatinib+Trastuzumab (Cohorts A+B) | Tucatinib Pre-Crossover (Cohort C) |
|---|---|---|
| Any TEAE | 82 | 28 |
| Tucatinib-related TEAE | 63 | 22 |
| Trastuzumab-related TEAE | 58 | NA |
| Any grade 3-5 TEAE | 33 | 8 |
| Trastuzumab-related grade 3-5 TEAE | 6 | NA |
| Tucatinib-related grade 3-5 TEAE | 8 | 2 |
| Any Treatment-Emergent Serious AE (TESAE) | 19 | 3 |
| Tucatinib-related TESAE | 3 | 1 |
| Trastuzumab-related TESAE | 2 | NA |
| TEAE leading to death | 0 | 0 |
| Discontinuation of any study treatment due to TEAE | 5 | 0 |
| Discontinuation of tucatinib due to TEAE | 5 | 0 |
| Discontinuation of tucatinib due to tucatinib-related TEAE | 2 | 0 |
| Discontinuation of trastuzumab due to TEAE | 3 | NA |
| Discontinuation of trastuzumab due to trastuzumab-related TEAE | 0 | NA |
AE: Any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs): Events that were new or worsened on or after receiving the first dose of study treatment (tucatinib or trastuzumab) and up through 30 days after the last dose of study treatment (tucatinib or trastuzumab). SAE: An event that at any dose led to death; life-threatening; required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Relatedness was judged by investigator According to NCI CTCAE version 4.03: Grade(G) 3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE.
| Participants | Tucatinib+Trastuzumab (Cohorts A+B) | Tucatinib Post-Crossover (Cohort C) |
|---|---|---|
| Any TEAE | 82 | 23 |
| Tucatinib-related TEAE | 64 | 15 |
| Trastuzumab-related TEAE | 59 | 13 |
| More than or equal to (>=) Grade 3 TEAE | 35 | 9 |
| Tucatinib-related >= grade 3 TEAE | 8 | 2 |
| Trastuzumab-related >= grade 3 TEAE | 6 | 2 |
| Any Treatment-Emergent Serious AE (TESAE) | 20 | 6 |
| Tucatinib-related TESAE | 3 | 0 |
| Trastuzumab-related TESAE | 2 | 2 |
| TEAE leading to death | 0 | 0 |
| Discontinuation of any study treatment due to TEAE | 5 | 2 |
| Discontinuation of tucatinib due to treatment-related TEAE | 2 | 2 |
| Discontinuation of tucatinib due to tucatinib-related TEAE | 2 | 2 |
| Discontinuation of trastuzumab due to treatment-related TEAE | 1 | 1 |
| Discontinuation of trastuzumab due to trastuzumab-related TEAE | 0 | 0 |
Dose modification included dose reduction and dose withheld by investigator due to AEs. Dose holds were defined as any instances where planned administration of the study drug was temporarily withheld or interrupted at the direction of the treating physician. Dose reductions of trastuzumab were not allowed; if trastuzumab could not be restarted after being held for a TEAE, it was discontinued.
| Participants | Tucatinib+Trastuzumab (Cohorts A+B) | Tucatinib Pre-Crossover (Cohort C) |
|---|---|---|
| Tucatinib dose held | 20 | 3 |
| Tucatinib dose reduced | 8 | 1 |
| Trastuzumab dose held | 24 | NA |
| Trastuzumab infusion interrupted (received full dose within 24 hrs) | 6 | NA |
| Trastuzumab infusion stopped early (full dose not received) | 1 | NA |
Dose modification included dose reduction and dose withheld by investigator due to AEs. Dose holds were defined as any instances where planned administration of the study drug was temporarily withheld or interrupted at the direction of the treating physician. Dose reductions of trastuzumab were not allowed; if trastuzumab could not be restarted after being held for a TEAE, it was discontinued. Drug interruption included infusion interrupted (full dose received within 24hrs).
| Participants | Tucatinib+Trastuzumab (Cohorts A+B) | Tucatinib Post-Crossover (Cohort C) |
|---|---|---|
| Tucatinib dose held | 23 | 7 |
| Tucatinib dose reduced | 9 | 2 |
| Trastuzumab dose held | 27 | 2 |
| Trastuzumab infusion interrupted | 6 | 0 |
The following hematology laboratory parameters were assessed: Hemoglobin decreased; leukocytes decreased; neutrophils decreased and Platelets decreased. Treatment emergent laboratory abnormalities were defined as abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v4.03 was used for the lab parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.
| Participants | Tucatinib+Trastuzumab (Cohorts A+B) | Tucatinib Pre-Crossover (Cohort C) |
|---|---|---|
| Hemoglobin decreased, Grade 1 | 28 | 6 |
| Hemoglobin decreased, Grade 2 | 8 | 2 |
| Hemoglobin decreased, Grade 3 | 3 | 0 |
| Hemoglobin decreased, Grade 4 | 0 | 0 |
| Leukocytes decreased, Grade 1 | 14 | 3 |
| Leukocytes decreased, Grade 2 | 5 | 0 |
| Leukocytes decreased, Grade 3 | 0 | 0 |
| Leukocytes decreased, Grade 4 | 0 | 0 |
| Neutrophils decreased, Grade 1 | 6 | 1 |
| Neutrophils decreased, Grade 2 | 2 | 1 |
| Neutrophils decreased, Grade 3 | 0 | 0 |
| Neutrophils decreased, Grade 4 | 0 | 0 |
| Platelets decreased, Grade 1 | 11 | 1 |
| Platelets decreased, Grade 2 | 2 | 2 |
| Platelets decreased, Grade 3 | 0 | 0 |
| Platelets decreased, Grade 4 | 0 | 0 |
The following hematology laboratory parameters were assessed: Hemoglobin decreased; hemoglobin increased; leukocytes decreased; lymphocytes decreased; neutrophils decreased and Platelets decreased. Treatment emergent laboratory abnormalities were defined as abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v4.03 was used for the lab parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.
| Participants | Tucatinib+Trastuzumab (Cohorts A+B) | Tucatinib Post-Crossover (Cohort C) |
|---|---|---|
| Hemoglobin decreased, All grades | 42 | 9 |
| Hemoglobin decreased, Grade 3 | 3 | 0 |
| Hemoglobin decreased, Grade 4 | 0 | 0 |
| Hemoglobin increased: All grades | 3 | 0 |
| Hemoglobin increased: Grade 3 | 0 | 0 |
| Hemoglobin increased: Grade 4 | 0 | 0 |
| Leukocytes decreased, All grades | 21 | 5 |
| Leukocytes decreased, Grade 3 | 0 | 0 |
| Leukocytes decreased, Grade 4 | 0 | 0 |
| Lymphocytes decreased, All grades | 25 | 11 |
| Lymphocytes decreased, Grade 3 | 6 | 1 |
| Lymphocytes decreased, Grade 4 | 0 | 0 |
| Neutrophils decreased: All grades | 10 | 0 |
| Neutrophils decreased: Grade 3 | 0 | 0 |
| Neutrophils decreased: Grade 4 | 0 | 0 |
| Platelets decreased, All grades | 15 | 4 |
| Platelets decreased, Grade 3 | 0 | 0 |
| Platelets decreased, Grade 4 | 0 | 1 |
The following chemistry laboratory parameters were assessed: Potassium increased; potassium decreased; aspartate aminotransferase increased; creatinine increased; alkaline phosphatase increased; total bilirubin increased. Treatment emergent laboratory abnormalities were defined as abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v5.0 was used for creatinine increased. NCI CTCAE v4.03 was used for the other laboratory parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.
| Participants | Tucatinib+Trastuzumab (Cohorts A+B) | Tucatinib Pre-Crossover (Cohort C) |
|---|---|---|
| Potassium increased, Grade 1 | 5 | 1 |
| Potassium increased, Grade 2 | 1 | 0 |
| Potassium increased, Grade 3 | 0 | 1 |
| Potassium increased, Grade 4 | 0 | 0 |
| Potassium decreased, Grade 1 | 13 | 3 |
| Potassium decreased, Grade 2 | 0 | 0 |
| Potassium decreased, Grade 3 | 1 | 1 |
| Potassium decreased, Grade 4 | 0 | 0 |
| Aspartate Aminotransferase increased, Grade 1 | 20 | 6 |
| Aspartate Aminotransferase increased, Grade 2 | 3 | 0 |
| Aspartate Aminotransferase increased, Grade 3 | 2 | 2 |
| Aspartate Aminotransferase increased, Grade 4 | 3 | 0 |
| Alanine Aminotransferase increased, Grade 1 | 31 | 4 |
| Alanine Aminotransferase increased, Grade 2 | 4 | 2 |
| Alanine Aminotransferase increased, Grade 3 | 2 | 2 |
| Alanine Aminotransferase increased, Grade 4 | 2 | 0 |
| Creatinine increased, Grade 1 | 38 | 9 |
| Creatinine increased, Grade 2 | 11 | 0 |
| Creatinine increased, Grade 3 | 0 | 0 |
| Creatinine increased, Grade 4 | 0 | 0 |
| Alkaline Phosphatase increased, Grade 1 | 16 | 4 |
| Alkaline Phosphatase increased, Grade 2 | 4 | 2 |
| Alkaline Phosphatase increased, Grade 3 | 1 | 0 |
| Alkaline Phosphatase increased, Grade 4 | 0 | 0 |
| Total Bilirubin increased, Grade 1 | 14 | 6 |
| Total Bilirubin increased, Grade 2 | 5 | 0 |
| Total Bilirubin increased, Grade 3 | 3 | 0 |
| Total Bilirubin increased, Grade 4 | 2 | 0 |
The following chemistry laboratory parameters were assessed: Potassium increased; potassium decreased; aspartate aminotransferase increased; creatinine increased; alkaline phosphatase increased; total bilirubin increased; albumin decreased; calcium corrected for albumin decreased; calcium corrected for albumin increased; glomerular filtration rate (GFR), estimated decreased; glucose decreased; glucose increased; sodium decreased; sodium increased; calcium and ionized increased. Treatment emergent laboratory abnormalities: Abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v5.0 used for creatinine increased. NCI CTCAE v4.03 used for the other laboratory parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.
| Participants | Tucatinib+Trastuzumab (Cohorts A+B) | Tucatinib Post-Crossover (Cohort C) |
|---|---|---|
| Potassium increased, All grades | 6 | 4 |
| Potassium increased, Grade 3 | 0 | 0 |
| Potassium increased, Grade 4 | 0 | 0 |
| Potassium decreased, All grades | 15 | 4 |
| Potassium decreased, Grade 3 | 1 | 0 |
| Potassium decreased, Grade 4 | 0 | 0 |
| Aspartate Aminotransferase increased, All grades | 29 | 9 |
| Aspartate Aminotransferase increased, Grade 3 | 2 | 3 |
| Aspartate Aminotransferase increased, Grade 4 | 3 | 0 |
| Alanine Aminotransferase increased, All grades | 39 | 7 |
| Alanine Aminotransferase increased, Grade 3 | 2 | 2 |
| Alanine Aminotransferase increased, Grade 4 | 2 | 0 |
| Creatinine increased, All grades | 50 | 10 |
| Creatinine increased, Grade 3 | 0 | 0 |
| Creatinine increased, Grade 4 | 0 | 0 |
| Alkaline Phosphatase increased, All grades | 21 | 3 |
| Alkaline Phosphatase increased, Grade 3 | 1 | 0 |
| Alkaline Phosphatase increased, Grade 4 | 0 | 0 |
| Total Bilirubin increased, All grades | 25 | 4 |
| Total Bilirubin increased, Grade 3 | 3 | 0 |
| Total Bilirubin increased, Grade 4 | 2 | 0 |
| Albumin decreased, All grades | 23 | 8 |
| Albumin decreased, Grade 3 | 1 | 0 |
| Albumin decreased, Grade 4 | 0 | 0 |
| Calcium Corrected for Albumin decreased, All grades | 11 | 5 |
| Calcium Corrected for Albumin decreased, Grade 3 | 0 | 0 |
| Calcium Corrected for Albumin decreased, Grade 4 | 0 | 0 |
| Calcium Corrected for Albumin increased, All grades | 8 | 5 |
| Calcium Corrected for Albumin increased, Grade 3 | 0 | 0 |
| Calcium Corrected for Albumin increased, Grade 4 | 0 | 0 |
| Glomerular Filtration Rate, Estimated decreased, All grades | 51 | 6 |
| Glomerular Filtration Rate, Estimated decreased, Grade 3 | 6 | 0 |
| Glomerular Filtration Rate, Estimated decreased, Grade 4 | 0 | 0 |
| Glucose decreased, All grades | 10 | 1 |
| Glucose decreased, Grade 3 | 0 | 0 |
| Glucose decreased, Grade 4 | 0 | 0 |
| Glucose increased, All grades | 48 | 9 |
| Glucose increased, Grade 3 | 2 | 0 |
| Glucose increased, Grade 4 | 0 | 0 |
| Sodium decreased, All grades | 18 | 1 |
| Sodium decreased, Grade 3 | 5 | 0 |
| Sodium decreased, Grade 4 | 0 | 0 |
| Sodium increased, All grades | 7 | 4 |
| Sodium increased, Grade 3 | 0 | 0 |
| Sodium increased, Grade 4 | 0 | 0 |
| Calcium, Ionized increased: All grades | 2 | 0 |
| Calcium, Ionized increased: Grade 3 | 0 | 0 |
| Calcium, Ionized increased: Grade 4 | 0 | 0 |
Vital signs included temperature, oxygen saturation, systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate and weight. Vital signs were considered clinically significant: temperature: \>= 38 degree Celsius (C); oxygen saturation less than (\<)88%; SBP \>=120 millimeters of mercury (mmHg) or DBP \>=80 mmHg; SBP \>=140 mmHg or DBP \>=90 mmHg; SBP \>=160 mmHg or DBP \>=100 mmHg and heart rate \>100 beats per minute (bpm) and maximum decrease from baseline in weight in kilograms (kg).
| Participants | Tucatinib+Trastuzumab (Cohorts A+B) | Tucatinib Post-Crossover (Cohort C) |
|---|---|---|
| Temperature >=38 degree C | 1 | 0 |
| Oxygen saturation <88% | 8 | 0 |
| SBP >= 120 mmHg or DBP >= 80 mmHg | 80 | 27 |
| SBP >= 140 mmHg or DBP >= 90 mmHg | 49 | 13 |
| SBP >= 160 mmHg or DBP >= 100 mmHg | 21 | 4 |
| Heart rate > 100 bpm | 26 | 5 |
| Maximum decrease from baseline in weight (kg) | 65 | 23 |
Collected over All-cause mortality: From start of study treatment to death by any cause (maximum up to 71.8 months); adverse events were followed during the safety reporting period (from Day 1 through 30 days after the last dose of study treatment) maximum up to 65.1 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tucatinib+Trastuzumab (Cohorts A+B) | 54/86 (62.8%) | 20/86 (23.3%) | 82/86 (95.3%) |
| Tucatinib Pre-Crossover (Cohort C) | 2/31 (6.5%) | 3/30 (10%) | 28/30 (93.3%) |
| Tucatinib Post-Crossover (Cohort C) | 15/28 (53.6%) | 6/28 (21.4%) | 23/28 (82.1%) |
| Event | Tucatinib+Trastuzumab (Cohorts A+B) | Tucatinib Pre-Crossover (Cohort C) | Tucatinib Post-Crossover (Cohort C) |
|---|---|---|---|
| Cardiac failureCardiac disorders | 0/86 | 0/30 | 1/28 |
| ConstipationGastrointestinal disorders | 0/86 | 0/30 | 1/28 |
| CholecystitisHepatobiliary disorders | 0/86 | 0/30 | 1/28 |
| Humerus fractureInjury, poisoning and procedural complications | 0/86 | 0/30 | 1/28 |
| Radius fractureInjury, poisoning and procedural complications | 0/86 | 0/30 | 1/28 |
| Ulna fractureInjury, poisoning and procedural complications | 0/86 | 0/30 | 1/28 |
| Ejection fraction decreasedInvestigations | 0/86 | 0/30 | 1/28 |
| Peripheral sensorimotor neuropathyNervous system disorders | 0/86 | 0/30 | 1/28 |
| Acute kidney injuryRenal and urinary disorders | 1/86 | 0/30 | 1/28 |
| Large intestinal obstructionGastrointestinal disorders | 3/86 | 0/30 | 0/28 |
| Event | Tucatinib+Trastuzumab (Cohorts A+B) | Tucatinib Pre-Crossover (Cohort C) | Tucatinib Post-Crossover (Cohort C) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 57/86 | 10/30 | 11/28 |
| FatigueGeneral disorders | 37/86 | 6/30 | 3/28 |
| NauseaGastrointestinal disorders | 29/86 | 5/30 | 2/28 |
| PyrexiaGeneral disorders | 18/86 | 3/30 | 6/28 |
| Back painMusculoskeletal and connective tissue disorders | 16/86 | 1/30 | 6/28 |
| Infusion related reactionInjury, poisoning and procedural complications | 18/86 | 0/30 | 4/28 |
| Abdominal painGastrointestinal disorders | 11/86 | 6/30 | 2/28 |
| Decreased appetiteMetabolism and nutrition disorders | 17/86 | 4/30 | 2/28 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 17/86 | 2/30 | 0/28 |
| ChillsGeneral disorders | 16/86 | 0/30 | 2/28 |
The Full Analysis Set included all participants who were enrolled and received any amount of study treatment and had human epidermal growth factor receptor 2+ (HER2+) tumors as defined by one or more protocol required local tests.
| Age, Continuous(Years) | Tucatinib+Trastuzumab (Cohort A) | Tucatinib+Trastuzumab (Cohort B) | Tucatinib Monotherapy (Cohort C) | Total |
|---|---|---|---|---|
| Median | 52 (24 to 71) | 57 (31 to 77) | 59.5 (29 to 75) | 56 (24 to 77) |
| Sex: Female, Male(Participants) | Tucatinib+Trastuzumab (Cohort A) | Tucatinib+Trastuzumab (Cohort B) | Tucatinib Monotherapy (Cohort C) | Total |
|---|---|---|---|---|
| Female | 19 | 14 | 15 | 48 |
| Male | 26 | 25 | 15 | 66 |
| Ethnicity (NIH/OMB)(Participants) | Tucatinib+Trastuzumab (Cohort A) | Tucatinib+Trastuzumab (Cohort B) | Tucatinib Monotherapy (Cohort C) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 1 | 4 |
| Not Hispanic or Latino | 35 | 29 | 25 | 89 |
| Unknown or Not Reported | 8 | 9 | 4 | 21 |
| Race (NIH/OMB)(Participants) | Tucatinib+Trastuzumab (Cohort A) | Tucatinib+Trastuzumab (Cohort B) | Tucatinib Monotherapy (Cohort C) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 2 | 1 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 | 6 |
| White | 37 | 28 | 23 | 88 |
| More than one race | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 3 | 8 | 4 | 15 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Tucatinib+Trastuzumab (Cohort A) | Tucatinib+Trastuzumab (Cohort B) | Tucatinib Monotherapy (Cohort C) | Total |
|---|---|---|---|---|
| Grade 0 | 24 | 26 | 17 | 67 |
| Grade 1 | 20 | 11 | 13 | 44 |
| Grade 2 | 1 | 2 | 0 | 3 |
| Region of Enrollment(Participants) | Tucatinib+Trastuzumab (Cohort A) | Tucatinib+Trastuzumab (Cohort B) | Tucatinib Monotherapy (Cohort C) | Total |
|---|---|---|---|---|
| North America | 45 | 24 | 16 | 85 |
| Europe | 0 | 15 | 14 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in Mar 2022, 57 months.
Results were first posted in Apr 2023, 1 year after primary completion.
Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 57 months is above that.
Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tucatinib